Background: Statins are the most commonly prescribed agents for hypercholesterolemia
because of their efficacy and tolerability. As the number of patients in need of statin therapy …

Background—Although statins reduce the risk of cardiovascular events, concerns about
adverse effects may deter physicians from prescribing these agents. We performed a …

ContextPrior intravascular ultrasound (IVUS) trials have demonstrated slowing or halting of
atherosclerosis progression with statin therapy but have not shown convincing evidence of …

The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter
trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin across dose …

Although LDL cholesterol (LDL‐C) is associated with an increased risk of coronary heart
disease, other lipoproteins and their constituents, apolipoproteins, may play an important …

The relationship between statin-induced increases in HDL cholesterol (HDL-C)
concentration and statin-induced decreases in LDL cholesterol (LDL-C) is unknown. The …

BACKGROUND:: The absolute frequencies of adverseevents (AEs) between statins and
placebo are very low in clinical trials, making clinical interpretation and application difficult …

Clinical data show that a 1% increase in serum concentrations of high-density lipoprotein
cholesterol (HDL-C) can decrease cardiovascular risk by 2% to 3%. Therefore, mechanisms …

The introduction of the hydroxy methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors
(statins) in 1987 was a major advance in the prevention and treatment of cardiovascular …

Rosuvastatin, a new statin, has been shown to possess a number of advantageous
pharmacological properties, including enhanced HMG‐CoA reductase binding …